Ilovetech, I am hampered in responding to your question because your #422218 link failed to provide any Merck litigation links. Merck’s been involved in numerous PTO reexamination matters dating back ~ 2 decades. Do you mean the Keytruda patents litigation referred to here?:

BeckersHospitalreview.com

The resolution is already present in post #/…’247, my original response to you. No waiting. I always will pay $15 co-pay in that particular CVS you called w/o a new coupon, may be $9 if I contact Amarin and get a new coupon. But do you have my gov’t insurance plan, GEHA? Note the most recent posts of DMC8 and CaptBeer re Vascepa becoming “preferred” drug to treat CVDs and for “longevity”.

Rmb, it’s the same Yahoo article that ramfan posted earlier today.

I see where physicians who not aware of Vascepa seem to be prescribing generic rapamycine for $sums that far exceed the yearly cost of Vascepa I pay. Vascepa should be able to compete, even off-label, with generic R and/or V. Your logic and rationale are sound. At near age 87, I am not thinking of using generic R or V. It is ironic that I was prescribed V, off-label, in 2012-2013.

DMC8, it might be worthwhile to post by copy/paste the pdf of the pictures/drawings and text of the short editorial article here as a record of what is going on diagnostically in the CRC test, if you can. I can’t tell if anybody actually did read any of the 4 NEJM articles I posted. I see some evidence that Bayer may be changing its business model to account for the potential disappearance of Cologuard from its sales picture, to be replaced by the blood marker test when/if FDA and EU approve it. Two new indications for Vascepa might result—treatment of CRC and metabolic syndrome are the potential new indications, IMO.

1500 Wilson Blvd in the back of the Target store location. There is a new, much larger CVS that recently opened a bit further up the hill on Wilson. We have not explored what is available in the new CVS. Spouse and I speculate that the rented space that CVS has in Target might close. Cut costs as it is almost across the street from the new Wilson CVS location though Target itself is large and likely provides the same/more goods(like electronics and extensive grocery items) that may not be available in the new CVS.

I wonder how long we wait for that $80?

And I thought the vet bills and subsequent urgent care bills for imaging our cat with a cat hospital stay of 3 days and nights were high. She was morose and ate nothing for quite a few days. Some surgery and appetite stimulating cream applied to her ears did wonders. Our cat is back home now happily eating/snacking and sleeping away. The vets at those 2 locations know what they’re doing.

I paid $15 co-pay at CVS also for a 3-month supply of Vascepa. Both of us should see if Amarin still has a coupon for $9 co-pay, and renew it if they do so we can present the new coupon to the pharmacist. Otoh, Amarin may have increased the coupon price to $15 co-pay. Inflation?

One of the clinical trials involving Vascepa is in CRC—Colorectal cancer, if I recall correctly. In the NEJM dated March 14, 2024, there are 2 original articles and 2 editorials dealing with the main article “A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening” at page 973.

DOI: 10.1056/NEJMoa2304714

DOI: 10.1056/NEJMe2311101 is one of the editorials titled “Science Behind the Study” at page 1047.
See also DOI: 10.1056/NEJMoa2310336 and DOI: 10.1056/NEJMe2400366

Did the FDA approval AH of MDGL’s MASH/NASH drug trim AMRN’s sails/potential sales?

I don’t think I said that, ilovetech.
First, look at the population of 600+ District Court judges. Some, like Judge Andrews in Delaware, will handle the usual patent infringement case readily. Experience!! The PTO does not deal with infringement issues, and validity issues(if simple) he will deal with. Complex validity issues coupled with a docket filled with, e.g., higher priority criminal cases(Speedy Trial Act) may be another story. Then, many judges will order the parties to seek reexamination of the patent(s) in the PTO to gain views and experience on patent validity of the 200+ experts on the PTO Board of Patent Appeals while they deal with priority cases on their docket.

dogn, I suggest that all here look for the Corporate Call and Q4 update for March 13, 2004 at Investor.Sangamo.com. I found this presentation on the ANI Pharmaceutical IHub board at post #14792. The 42 slides(reflecting preclinical research in animals) are impressive. (My hope is that the researchers at the U.Wisconsin have completed or are currently assessing the cells of human patients in the Amarin-funded BRAVE trial using the same or similar technology). The SGMO cell images appear to be enabled by NVDA AI technology/chips, and have caused SGMO to change its business model to focus on development of technology in 4 areas of the brain, e.g., prion disease and Alzheimer’s disease, as well as novel chronic neuropathic pain therapeutics. PFE is financing the preclinical Prion Disease and AD area so far, and Alexion and Takeda are partners in 2 other areas

That last trade at $0.90 was deliberate on my part, sleven.

With my insurance being managed by PBM Caremark at my local CVS, my latest co-pay continues to be $15 for a 3 month supply of Vascepa, prescription filled 2/27/2024. I have no reason to ask for any generic Vascepa to fill that prescription. Generic Vascepa is no longer available or covered at my local CVS.

From memory, looks like EPA v. DHA.(?)

Maybe I do not understand the Device Specifications written on the instruction for use form enclosed inside the product box. There it says, under Expected Service Life:

…..Up to 720 hours (on/off capability)
…..Up to 168 hours (continuous)

I expected 168 hours but actually received ~ 720 hours, 1 month.

How long will it take Amarin to bring that MND-2119 based product to market, predicated on FDA approval of same? A new NDA? AdCom? A sNDA? Will PFE agree to sell a new Vascepa product form in Canada? How long will it take the U.S., the Canadian provinces, and the rest of the world to approve suitable/sufficient remuneration for the new Vascepa dosage form?

Biel extended the life of its Recovery product. Did Biel ever extend the life of its ActiPatch product?

I fell on my left hip over a month ago. No bone breakage. I went to my chiropractor about a month ago. He has adjusted placement of ActiPatch ring surrounding the sore/pain area on each twice a week visit, and yesterday the light went out after that MONTH of 24/7 wear. My M.D. spouse placed a new ActiPatch. I am now mostly pain free, and doing my best to develop a posture where I do not look down constantly. Lidocaine patch and Alleve capsules helped also.

See also #422108 and related posts and replies. Methinks Tats has ignored that conversation and effects thereof.

Wow! This proposed schedule in all cases filed by Amarin is certainly worth knowing about. I think I see where these cases are/might be going, and I see why Hikma et al are opposing this Amarin schedule. Has TEVA or Takeda said anything about new proposed schedule yet? The time periods in which fact discovery ends and Amarin may amend its complaints to include other parties will prove interesting to CaptBeer, Tats, you, me and everyone else if my speculation is correct. More later, if necessary.

This post raises questions whether Eastern CapitalKen Dart is now/will be collaborating with Sarissa/Alex Denner in raising share price of CDMO to higher/former level above $6.50.

Lost pacer account when I retired, and now depend on others. CaptBeer, DMC8, anyone else: Is there anything in that letter in the D.N.J. antitrust case worth knowing about? Please post text.

The status update usually enables the proposed schedule of future events in the case to become effective. End of discovery, filing of expert reports, arbitration schedule, trial dates, etc.

The claims of that Mochida patent are at pages 71-72. Most pages are devoted to numbered paragraphs of the specification that support the claims. Thanks for the link.

I still wonder whether the present CAFC appeal will settle before oral arguments in early April. Recall that the magistrate judge in D.N.J. has set a date for Doctor Reddy to update the status of the antitrust case that expires soon, this week I think.

FDA advises LLY it wants AdCom meeting. Portends delay. Meanwhile NVO CEO was interviewed on CNBC-TV this morning, repeats NVO’s PR warning dated in January 2024 that it will not have manufacturing capacity to fill demand for its weight loss drug until 2006(?).

Still unusual for NVO CEO to appear on TV to reiterate old news. 3-5 minute interview.

Did you see NVO’s CEO on CNBC-TV this morning, saying it would be years(2026) before NVO had sufficient manufacturing capacity to produce enough Ozempic to compete with LLY?

Repeat the question posted previously: A.S. and his ANIP and MedPage possible M&A activities.

NVO’s Wegovy was just given FDA approval for treatment of CVDs, per CNBC-TV alert. No AMRN worries here(?).The CEO of NVO appeared on CBC-TV earlier this morning, saying they had manufacturing capacity problems for Ozempic and that it would be a number of years before NVO could catch up with LLY. Wegovy and Ozempic are the same molecule. Am I missing something? Does NVO have sufficient manufacturing capacity for Wegovy because it is a different dosage form? Anybody know from Europe?

I wonder whether ANIP(Schwarz) or MedPage(Schwarz) has contacted CDMO for ANY reason, potential customer or otherwise. See ANIP PRs dated 11/2023 to date, available from TD Ameritrade and ANIP IHub board.

You might add LTRN as a stock to look at, recent PRs dated 11/28/2003 up to yesterday, available from TD Ameritrade.

No one has responded yet to a question I had about LEXX, and its proprietary drug delivery system that is said to improve the way molecules(like VKTX has) enter the bloodstream. See the various PRs of LEXX dated in January 2024, available from TD Ameritrade. The clinical trials of LEXX are early, but both company shares are + substantially this year. The term “blockbuster” is used to describe the combination of the various VKTX molecules in its pipeline and the LEXX delivery system.

PFE just won a suit in the 2nd Circuit Court of Appeals that involved its diversity fellowship program. PFE share price jumped as a result to current $27.13.

See BIEL PR dated 2/23/2024. Delayed market reaction that was not priced in to current share price? Or shorts moving out?

Perhaps it is the result of a delayed market reaction to the ATNM PR dated 2/28/2024.

Identity of judges on panel D will be known when we arrive on 2nd floor by 9:30 a.m. Thanks for the update. Spouse and I plan to be there.

A new notice of allowance for a patent application, titled:

Compositions And Methods For Detecting Predisposition To Cardiovascular Disease.

I wouldn’t phrase it that way, but we now have > 20k% return on original investment in NVDA.

I have a minor amount of shares of LWLG with a minor loss. Ask Steve Schietz(sp?) if he understands the quote from me that you posted. He liked Polestar. At the moment I spend more time trying to keep up with the Magnificent 7 in our portfolios, headed by NVDA that I bought split-adjusted 755 shares at cost of $4.31 about a decade ago. The auto market is a subset along with biotech(you might check VKTX and LEXX in 2023-2024). All for now. A lunch or dinner should help us understand each other.